Drug Predictions & Odds· 265 markets
FDA approves Leqembi auto-injection for early Alzheimer’s?
$2k Vol.
$0 Liq.
12
Ended
$2k Vol.$0 Liq.12Ended
Yes
FDA approves Telix Pharmaceuticals’ TLX250-CDx for kidney cancer imaging?
$3k Vol.
$0 Liq.
12
Ended
$3k Vol.$0 Liq.12Ended
No
FDA approves Precigen’s PRGN-2012 for recurrent respiratory papillomatosis?
$15k Vol.
$0 Liq.
12
Ended
$15k Vol.$0 Liq.12Ended
Yes
No
FDA approves Sanofi’s Rilzabrutinib for immune thrombocytopenia?
$3k Vol.
$0 Liq.
12
Ended
$3k Vol.$0 Liq.12Ended
Yes
FDA approves Capricor Therapeutics’ Deramiocel for Duchenne muscular dystrophy by August 31?
$11k Vol.
$0 Liq.
12
Ended
$11k Vol.$0 Liq.12Ended
No
FDA approves PTC Therapeutics’ Vatiquinone for Friedreich’s ataxia?
$2k Vol.
$0 Liq.
12
Ended
$2k Vol.$0 Liq.12Ended
No
FDA approves Tonix Pharmaceuticals’ TNX-102 SL for fibromyalgia?
$916 Vol.
$0 Liq.
12
Ended
$916 Vol.$0 Liq.12Ended
Yes
Yes
FDA approves LENZ Therapeutics’ LNZ100 for presbyopia by August 31?
$7k Vol.
$0 Liq.
12
Ended
$7k Vol.$0 Liq.12Ended
Yes
TransCon hGH (sBLA)
No
FDA approves Regeneron’s Dupixent for bullous pemphigoid?
$2k Vol.
$0 Liq.
32
Ended
$2k Vol.$0 Liq.32Ended
Yes
FDA approves Merck’s clesrovimab infant RSV prevention (MK‑1654)?
$23k Vol.
$0 Liq.
3
Ended
$23k Vol.$0 Liq.3Ended
Yes